EUVIMEDEUVIMED entdecken
Editorial

A New Antibody Treatment for Migraine

Elizabeth Loder

New England Journal of Medicine · 05.09.2024 · 391 (9) · 855-857

DOI: 10.1056/nejme2406401 ↗

Kurz gefasst

Editorial in der Zeitschrift New England Journal of Medicine, erschienen am 05.09.2024. Verfasst von Elizabeth Loder. Beteiligte Einrichtung: From Brigham and Women's Hospital, Boston. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Migraine Disorders, Pituitary Adenylate Cyclase-Activating Polypeptide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedMigraine DisordersPituitary Adenylate Cyclase-Activating PolypeptideHumansRandomized Controlled Trials as TopicClinical Trials, Phase II as TopicMulticenter Studies as TopicInfusions, IntravenousSymptom Flare Up

Substanzen

Antibodies, Monoclonal, HumanizedPituitary Adenylate Cyclase-Activating Polypeptide

Autor:innen und Institutionen

  • From Brigham and Women's Hospital, Boston.

Zitieren

APA

Loder, E. (2024). A New Antibody Treatment for Migraine. New England Journal of Medicine, 391(9), 855-857. https://doi.org/10.1056/nejme2406401

Vancouver

Loder E. A New Antibody Treatment for Migraine. New England Journal of Medicine. 2024;391(9):855-857. doi:10.1056/nejme2406401

BibTeX
@article{Loder2024,
  author = {Loder, Elizabeth},
  title = {A New Antibody Treatment for Migraine},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {9},
  pages = {855--857},
  doi = {10.1056/nejme2406401}
}
Kostenlos starten →